Evidence map›Paper›PMID 37236523›Full record

ReviewDrug discovery today2023

Modulating GPCR and 14-3-3 protein interactions: Prospects for CNS drug discovery.

Sathapana Kongsamut, Haifeng Eishingdrelo

Open access · hybridAbstract readReview
In one paragraph

Review in Drug discovery today, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Sathapana KongsamutResearch Institute for Scientists Emeriti, Drew University, 36 Madison Avenue, Madison, NJ 07940, USA.
Haifeng EishingdreloBioInvenu, 50 Williams Parkway, Unit A2, East Hanover, NJ 07936, USA. Electronic address: haifeng.eishingdrelo@bioinvenu.com.
BioInvenu (United States) · USDrew University · US

Funding

Novel tools for investigating GPCR-mediated 14-3-3 signaling pathwayR44MH108203 · NIMH · BIOINVENU CORPORATION · PI EISHINGDRELO, HAIFENG · 2017 to 2018
$1.5M
Screen molecules modulating MOR trafficking with a newly developed MOR/14-3-3 bioassay.R43DA050264 · NIDA · BIOINVENU CORPORATION · PI EISHINGDRELO, HAIFENG · 2019 to 2019
$321k
NIDA NIH HHS R43 DA050264NIMH NIH HHS R44 MH108203
6 · The paper itself

Abstract

The activation of G-protein-coupled receptors (GPCRs) triggers a series of protein-protein interaction events that subsequently induce a chain of reactions, including alteration of receptor structures, phosphorylation, recruitment of associated proteins, protein trafficking and gene expression. Multiple GPCR signaling transduction pathways are evident - two well-studied pathways are the GPCR-mediated G-protein and β-arrestin pathways. Recently, ligand-induced interactions between GPCRs and 14-3-3 proteins have been demonstrated. This linking of GPCRs to 14-3-3 protein signal hubs opens up a whole new realm of signal transduction possibilities. 14-3-3 proteins play a key part in GPCR trafficking and signal transduction. GPCR-mediated 14-3-3 protein signaling can be harnessed for the study of GPCR function and therapeutics.

Indexed as

14-3-3 ProteinsSignal Transductionbeta-ArrestinsDrug DiscoveryReceptors, G-Protein-Coupled14-3-3 Proteinsbeta-ArrestinsReceptors, G-Protein-Coupled

Identifiers

PMID37236523
PMCPMC10524340
OpenAlexW4378070914

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.